About the Company
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company's proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
269
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $RUBY News
Rubius Therapeutics, Inc. Common Stock (RUBY)
Nasdaq provides company’s SEC filings, which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC ...
Vacant Rubius property generating interest after 1 year on market
Despite remaining vacant one year after its purchase by Boston-based The Davis Cos., the former Rubius Therapeutics facility ...
Rubius Doubles on Progress in Early-Stage Cancer-Drug Trial
Shares of Rubius Therapeutics more than doubled after the biotech reported progress in an early-stage trial of a cancer drug. Rubius Therapeutics (RUBY) more than doubled Monday after the ...
Red Cell Therapeutics: realizing the promise of cellular medicine
Rubius Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, USA, that is developing allogeneic cell therapies based on biologically engineered red blood cells (RBCs).
Next-generation PARP inhibitor demonstrates clinical benefit in patients with homologous recombination repair-deficient breast cancer
Saruparib, a selective inhibitor of poly-ADP ribose polymerase 1 (PARP1), demonstrated a promising objective response rate and progression-free survival in patients with certain homologous ...
FULC Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high ...
Intellia Therapeutics Inc NTLA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
ATXS Astria Therapeutics, Inc.
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States.
Outlook Therapeutics, Inc. (OTLK)
ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of ...
Flagship Ventures Fund IV-Rx, L.P.'s Net Worth
Who is Flagship Ventures Fund IV-Rx, L.P.? Flagship Ventures Fund IV-Rx, L.P. has an estimated net worth of $4.78 Billion. This is based on reported shares across multiple companies, which include ...
Rubius Therapeutics, Inc. (RUBY)
*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Loading the latest forecasts...